- Home
- PHGE vs SNSE Comparison
PHGE vs SNSE Comparison
Compare PHGE & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- SNSE
- Stock Information
- Founded
- PHGE 2015
- SNSE 2005
- Country
- PHGE Israel
- SNSE United States
- Employees
- PHGE N/A
- SNSE N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- SNSE Health Care
- Exchange
- PHGE Nasdaq
- SNSE Nasdaq
- Market Cap
- PHGE 10.4M
- SNSE 10.8M
- IPO Year
- PHGE N/A
- SNSE 2021
- Fundamental
- Price
- PHGE $0.56
- SNSE $8.68
- Analyst Decision
- PHGE Strong Buy
- SNSE Strong Buy
- Analyst Count
- PHGE 1
- SNSE 4
- Target Price
- PHGE $15.00
- SNSE $72.50
- AVG Volume (30 Days)
- PHGE 12.4M
- SNSE 33.7K
- Earning Date
- PHGE 08-13-2025
- SNSE 08-05-2025
- Dividend Yield
- PHGE N/A
- SNSE N/A
- EPS Growth
- PHGE N/A
- SNSE N/A
- EPS
- PHGE N/A
- SNSE N/A
- Revenue
- PHGE N/A
- SNSE N/A
- Revenue This Year
- PHGE N/A
- SNSE N/A
- Revenue Next Year
- PHGE N/A
- SNSE N/A
- P/E Ratio
- PHGE N/A
- SNSE N/A
- Revenue Growth
- PHGE N/A
- SNSE N/A
- 52 Week Low
- PHGE $0.34
- SNSE $5.00
- 52 Week High
- PHGE $1.90
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- PHGE 57.85
- SNSE 57.34
- Support Level
- PHGE $0.48
- SNSE $7.34
- Resistance Level
- PHGE $0.59
- SNSE $8.23
- Average True Range (ATR)
- PHGE 0.07
- SNSE 1.03
- MACD
- PHGE 0.01
- SNSE 0.03
- Stochastic Oscillator
- PHGE 52.48
- SNSE 50.48
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).